{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:36:24Z","timestamp":1777934184716,"version":"3.51.4"},"reference-count":50,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2010,9,22]],"date-time":"2010-09-22T00:00:00Z","timestamp":1285113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:p>It is estimated that almost one-third of adverse reactions to pharmaceutical agents result from drug interactions. The potential for drug interactions in oncology complicates the pharmacist\u2019s role of finding a balance between efficacy and acceptable toxicity for all agents involved (anticancer agents, supportive therapies, and concomitant medications). In the realm of metastatic breast cancer, the heavily pretreated nature of many patients and the narrow therapeutic window associated with most therapies puts all patients at risk for drug interactions. In practice, co-administration of a pharmacological agent with the potential to alter the clinical profile of the patient\u2019s anticancer regimen may be unavoidable. Herein are discussed underlying molecular mechanisms that are usually responsible for drug interactions in the realm of breast oncology. Since more and more oral anticancer agents are emerging onto the market or are in late clinical development, special consideration is given to identification and management of potential interactions associated with oral anticancer therapeutics. In addition, recommendations are provided for dose reduction strategies, effective monitoring, management of drug interactions, and communication strategies with patients and other members of the clinical team.<\/jats:p>","DOI":"10.1177\/1078155210379167","type":"journal-article","created":{"date-parts":[[2010,9,23]],"date-time":"2010-09-23T00:18:26Z","timestamp":1285201106000},"page":"236-245","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Drug interactions in metastatic breast cancer"],"prefix":"10.1177","volume":"17","author":[{"given":"Timothy","family":"Tyler","sequence":"first","affiliation":[{"name":"Comprehensive Cancer Center, Desert Regional Medical Center, 1180 North Indian Canyon Drive Suite E-218, Palm Springs, CA 92262, USA,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,9,22]]},"reference":[{"key":"atypb1","volume-title":"Arimidex\u00ae (anastrozole) [package insert]","year":"2009"},{"key":"atypb2","volume-title":"Aromasin\u00ae (exemestane) [package insert]","year":"2008"},{"key":"atypb3","volume-title":"Faslodex\u00ae (fulvestrant) [package insert]","year":"2005"},{"key":"atypb4","volume-title":"Femara\u00ae (letrozole) [package insert]","year":"2009"},{"key":"atypb5","volume-title":"Nolvadex\u00ae (tamoxifen citrate) [package insert]","year":"2005"},{"key":"atypb6","volume-title":"Clinical Pharmacology Web site","year":"2009"},{"key":"atypb7","volume-title":"Zoladex\u00ae (goserelin acetate implant) [package insert]","year":"2009"},{"key":"atypb8","volume-title":"Xeloda\u00ae (capecitabine) [package insert]","year":"2006"},{"key":"atypb9","volume-title":"Taxotere\u00ae (docetaxel) [package insert]","year":"2007"},{"key":"atypb10","volume-title":"Gemzar\u00ae (gemcitabine) [package insert]","year":"2006"},{"key":"atypb11","volume-title":"Ixempra\u00ae (ixabepilone) [package insert]","year":"2009"},{"key":"atypb12","volume-title":"Taxol\u00ae (paclitaxel) [package insert]","year":"2007"},{"key":"atypb13","volume-title":"Abraxane\u00ae (nanoparticle albumin-bound paclitaxel) [package insert]","year":"2009"},{"key":"atypb14","volume-title":"Avastin\u00ae (bevacizumab) [package insert]","year":"2009"},{"key":"atypb15","volume-title":"Tykerb\u00ae (lapatinib) [package insert]","year":"2008"},{"key":"atypb16","volume-title":"Herceptin\u00ae (trastuzumab) [package insert]","year":"2008"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.55"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1887"},{"key":"atypb19","unstructured":"Nies A. and Spielberg SP Principles of therapeutics. In: Hardman J , Limbird LE and Molinoff PB (eds) Goodman and Gilman\u2019s the pharmacological basis of therapeutics, 9th edn. New York, NY: The McGraw-Hill Companies, 1996, p.43-45."},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008360406322"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124100-00001"},{"key":"atypb22","unstructured":"Ando Y. Drug interactions in cancer therapy: Pharmacodynamic drug interactions. In: Figg WD and McLeod HL (eds) Handbook of anticancer pharmacokinetics and pharmacodynamics . Totowa, NJ: Humana Press, 2004, p.215-230."},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443150-00005"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.182"},{"key":"atypb25","volume-title":"Adriamycin\u00ae (doxorubicin hydrochloride) [package insert]","year":"2006"},{"key":"atypb26","volume-title":"Cytoxan\u00ae (cyclophosphamide) [package insert]","year":"2000"},{"key":"atypb27","volume-title":"Ellence\u00ae (epirubicin hydrochloride) [package insert]","year":"2005"},{"key":"atypb28","volume-title":"Abitrexate\u00ae (generic) [package insert]","year":"2004"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70385-6"},{"key":"atypb30","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.112240"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-002-8424-8"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.18433\/J3RC77"},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1021\/tx970192k"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.079608"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011089924099"},{"key":"atypb36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.12.081"},{"key":"atypb37","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.17.467"},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-171389"},{"key":"atypb39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.8.1780"},{"key":"atypb40","doi-asserted-by":"publisher","DOI":"10.2174\/138920008784220664"},{"key":"atypb41","doi-asserted-by":"publisher","DOI":"10.2174\/138161208784139738"},{"key":"atypb42","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-09-0516"},{"key":"atypb43","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1640"},{"key":"atypb44","doi-asserted-by":"publisher","DOI":"10.2174\/138920008786927776"},{"key":"atypb45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03303.x"},{"key":"atypb46","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.121829"},{"key":"atypb47","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.41.1.101"},{"key":"atypb48","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200522030-00005"},{"key":"atypb49","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.51"},{"key":"atypb50","first-page":"548","volume":"4","author":"Jain KK","year":"2002","journal-title":"Curr Opin Mol Ther"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155210379167","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155210379167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:14:00Z","timestamp":1777688040000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155210379167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,22]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1177\/1078155210379167"],"URL":"https:\/\/doi.org\/10.1177\/1078155210379167","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,22]]}}}